Abcellera Biologics Inc
Change company Symbol lookup
Select an option...
ABCL Abcellera Biologics Inc
OCAXW OCA Acquisition Equity Warrant Exp 14 Jan 2026 *W EXP 01/31/2028
ABBV Abbvie Inc
IIIN Insteel Industries Inc
KO Coca-Cola Co
MOD Modine Manufacturing Co
WABC Westamerica Bancorp
LUV Southwest Airlines Co
COF-K Capital One Financial Corp
NDAQ Nasdaq Inc
Go

Health Care : Life Sciences Tools & Services | Mid Cap Blend
Based in Canada
Company profile

AbCellera Biologics Inc. (AbCellera) is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.

Closing Price
$14.55
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
16

10-day average volume:
1,737,979
16

Display:

Providers:

UpdateCancel
6 providers
Yesterday's News, December 07, 2021
AbCellera Announces Changes to Its Board of Directors

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and...(BusinessWire)

December 03, 2021
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12

AbCellera (Nasdaq: ABCL) today announced the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include pediatric patients under the age of 12...(BusinessWire)

December 02, 2021
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today the appointment of Neil Aubuchon as Chief Commercial Officer (CCO). Mr. Aubuchon brings over 20 years of...(BusinessWire)

November 09, 2021
AbCellera Reports Q3 2021 Business Results

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the third quarter of 2021. All financial information in this press release is reported...(BusinessWire)

November 04, 2021
AbCellera Announces Virtual Presentations at Investor Conferences in November

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following virtual investor conferences: Credit Suisse 30th Annual Virtual Healthcare Conference on Thursday, November 11 at 7:30 a.m. Pacific Time Stifel...(BusinessWire)

November 02, 2021
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19

AbCellera (Nasdaq: ABCL) today announced an additional purchase by the U.S. government from Eli Lilly and Company (Lilly) for bamlanivimab with etesevimab for administration together. This neutralizing antibody therapy is authorized for emergency...(BusinessWire)

October 14, 2021
AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021

AbCellera (Nasdaq: ABCL) will announce its third quarter 2021 financial results on Tuesday, November 9, 2021, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. (BusinessWire)

September 22, 2021
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by...(PR Newswire)

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by...(BusinessWire)

September 21, 2021
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19

AbCellera (Nasdaq: ABCL) today announced the European Commission (EC) and Eli Lilly and Company (Lilly) have entered into a Joint Procurement Agreement to supply up to 220,000 doses of bamlanivimab together with etesevimab to treat confirmed...(BusinessWire)

September 17, 2021
Thinking about buying stock in Corvus Pharmaceuticals, AbCellera Biologics, Rekor Systems, SmileDirectClub, or Arcus Biosciences?

InvestorsObserver issues critical PriceWatch Alerts for CRVS, ABCL, REKR, SDC, and RCUS. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

September 16, 2021
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19

AbCellera (Nasdaq: ABCL) today announced the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg administered with etesevimab (LY-CoV016) 1400 mg to include post-exposure...(BusinessWire)

September 15, 2021
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines

AbCellera (Nasdaq: ABCL) announced today that it entered into a multi-year, multi-target research collaboration and license agreement with Moderna to leverage AbCellera's AI-powered technology to search and analyze natural immune responses to...(BusinessWire)

September 13, 2021
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has acquired TetraGenetics, Inc. (TetraGenetics), a biotechnology company with a proprietary platform for...(BusinessWire)

September 10, 2021
AbCellera to Present Virtually at the BofA Securities - Tech Solutions for Drug Discovery Conference

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the BofA Securities - Tech Solutions for Drug Discovery Conference on Monday, September 20, 2021, at 9:00 a.m. Pacific Time. (BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.